On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer’s disease or for patients with mild cognitive impairment. This drug, lecanemab, moderately slows the rate of cognitive decline in a way that is noticeable to patients. The Hospital Universitari General de Catalunya, through the Clinical Research Unit (UDIC) led by…
This study could improve the efficacy and safety of the products being evaluated to try to modify the progressive course of mild to moderate prodromal Alzheimer’s disease. In this research, which is identified with the name Brain shuttle, a solution to the difficulty of access of drugs inside the central nervous system is proposed. It…
Grifols has reported to the press the positive result of the AMBAR trial in patients with Alzheimer’s disease in a moderate phase. Our unit (located in the General University Hospital of Catalonia) participated in this phase II clinical trial. Patients were treated with several plasmapheresis and albumin replacement, with or without immunoglobulins administration, compared to…
Our team participated in a phase II clinical trial, with an antiamyloid monoclonal antibody in mild Alzheimer, which was positive. We have started the open label extension for the patients who participated in this phase II study. We also started the development of the phase III clinical trial with this antiamyloid monoclonal antibody of EISAI…
We have initiated a clinical trial to assess the efficacy and safety of a drug that inhibits the proteases of a bacterium (P.gingivalis) that is detected in the brains of Alzheimer’s patients. It is a new approach to this pathology, absolutely different from the rest of ongoing projects. More information at www.gaintrial.com.
